These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16204393)

  • 1. Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics.
    Devlin JW; Welage LS; Olsen KM
    Ann Pharmacother; 2005 Nov; 39(11):1844-51. PubMed ID: 16204393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton pump inhibitor formulary considerations in the acutely ill. Part 1: Pharmacology, pharmacodynamics, and available formulations.
    Devlin JW; Welage LS; Olsen KM
    Ann Pharmacother; 2005 Oct; 39(10):1667-77. PubMed ID: 16118266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding: a meta-analysis.
    Khuroo MS; Khuroo MS; Farahat KL; Kagevi IE
    J Gastroenterol Hepatol; 2005 Jan; 20(1):11-25. PubMed ID: 15610441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
    Lucas LM; Gerrity MS; Anderson T
    Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton pump inhibitor therapy: preliminary results of a therapeutic interchange program.
    Amidon PB; Jankovich R; Stoukides CA; Kaul AF
    Am J Manag Care; 2000 May; 6(5):593-601. PubMed ID: 10977467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton pump inhibitors and hospital discharge rates for gastrointestinal events in Italy: a national ecological study.
    Russo P; Brutti C
    Clin Ther; 2007 Apr; 29(4):751-8. PubMed ID: 17617299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage.
    Spiegel BM; Dulai GS; Lim BS; Mann N; Kanwal F; Gralnek IM
    Clin Gastroenterol Hepatol; 2006 Aug; 4(8):988-997. PubMed ID: 16844422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children.
    Canani RB; Cirillo P; Roggero P; Romano C; Malamisura B; Terrin G; Passariello A; Manguso F; Morelli L; Guarino A;
    Pediatrics; 2006 May; 117(5):e817-20. PubMed ID: 16651285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous proton pump inhibitor therapy: a rationale for use.
    Armstrong D
    Rev Gastroenterol Disord; 2005; 5 Suppl 2():S18-30. PubMed ID: 16369224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton pump inhibitors for acid suppression in the intensive care unit: formulary considerations.
    Devlin JW
    Am J Health Syst Pharm; 2005 May; 62(10 Suppl 2):S24-30. PubMed ID: 15905598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comment: Proton pump inhibitor formulary considerations in the acutely ill. Part 1: pharmacology, pharmacodynamics, and available formulations.
    Conrad SA
    Ann Pharmacother; 2006 May; 40(5):997; author reply 997-8. PubMed ID: 16608907
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of stress ulcer prophylaxis algorithm study.
    Coursol CJ; Sanzari SE
    Ann Pharmacother; 2005 May; 39(5):810-6. PubMed ID: 15811900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton pump inhibitor utilization patterns in infants.
    Barron JJ; Tan H; Spalding J; Bakst AW; Singer J
    J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):421-7. PubMed ID: 18030207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative dosing for PPI therapy: rationale and options.
    Johnson DA
    Rev Gastroenterol Disord; 2003; 3 Suppl 4():S10-5. PubMed ID: 14671509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective.
    Freston JW
    Am J Gastroenterol; 1997 Apr; 92(4 Suppl):51S-55S; discussion 55S-57S. PubMed ID: 9127627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalisation due to peptic ulcer disease.
    Höer A; Gothe H; Schiffhorst G; Sterzel A; Grass U; Häussler B
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):854-8. PubMed ID: 17323403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Is the successful eradication of Helicobacter pylori sufficient for the healing of peptic ulcer?].
    Pregun I; Herszényi L; Juhász M; Miheller P; Tulassay Z
    Orv Hetil; 2006 Mar; 147(10):435-9. PubMed ID: 16573172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
    Chung SJ; Lee DH; Kim N; Jung SH; Kim JW; Hwang JH; Park YS; Lee KH; Jung HC; Song IS
    Hepatogastroenterology; 2007 Jun; 54(76):1293-6. PubMed ID: 17629092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing the shift of patients from one proton pump inhibitor to another: the effect of direct-to-consumer advertising.
    Hansen RA; Shaheen NJ; Schommer JC
    Clin Ther; 2005 Sep; 27(9):1478-87. PubMed ID: 16291421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.